GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Medicines Corp Ltd (SHSE:600511) » Definitions » Valuation Rank

China National Medicines (SHSE:600511) Valuation Rank


View and export this data going back to 2002. Start your Free Trial

What is China National Medicines Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


China National Medicines Valuation Rank Related Terms

Thank you for viewing the detailed overview of China National Medicines's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Medicines (SHSE:600511) Business Description

Traded in Other Exchanges
N/A
Address
No. 12 A, Sanyuan West Lane, Yongwai, Chongwen District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company is also engaged in proprietary Chinese medicines, Chinese medicine decoction pieces, Chinese medicinal materials, chemical preparations, chemical raw materials, antibiotics, and biochemical drugs.
Executives
Chen Zhang Qing Director